ACELYRIN, INC. Common Stock (SLRN) - Total Liabilities
Based on the latest financial reports, ACELYRIN, INC. Common Stock (SLRN) has total liabilities worth $29.27 Million USD as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
ACELYRIN, INC. Common Stock - Total Liabilities Trend (2021–2024)
This chart illustrates how ACELYRIN, INC. Common Stock's total liabilities have evolved over time, based on quarterly financial data. See ACELYRIN, INC. Common Stock (SLRN) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
ACELYRIN, INC. Common Stock Competitors by Total Liabilities
The table below lists competitors of ACELYRIN, INC. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
E. W. Scripps Co Class A
NASDAQ:SSP
|
USA | $3.67 Billion |
|
Metall Zug AG
SW:METN
|
Switzerland | CHF217.76 Million |
|
Zalaris ASA
OL:ZAL
|
Norway | Nkr941.88 Million |
|
Asuransi Tugu Pratama Indonesia Tbk PT
JK:TUGU
|
Indonesia | Rp17.53 Trillion |
|
Hawthorn Bancshares Inc
NASDAQ:HWBK
|
USA | $1.72 Billion |
|
Montauk Renewables Inc
NASDAQ:MNTK
|
USA | $122.58 Million |
|
Ellomay Capital Ltd
TA:ELLO
|
Israel | ILA726.55 Million |
|
Luca Mining Corp.
V:LUCA
|
Canada | CA$125.31 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down ACELYRIN, INC. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see SLRN stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 18.43 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ACELYRIN, INC. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ACELYRIN, INC. Common Stock (2021–2024)
The table below shows the annual total liabilities of ACELYRIN, INC. Common Stock from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $32.85 Million | -61.96% |
| 2023-12-31 | $86.35 Million | -80.57% |
| 2022-12-31 | $444.35 Million | +207.81% |
| 2021-12-31 | $144.36 Million | -- |
About ACELYRIN, INC. Common Stock
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is lonigutamab, a subcutaneously delivered monoclonal antibody targeting IGF-1R, which has completed Phase 2 clinical trial for the treatment of Thyroid Eye Disease (TED). Acelyrin, Inc. was incorp… Read more